February 27, 2012
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company Dendreon (Nasdaq: DNDN ) plunged 18% on Monday after the company's quarterly results disappointed Wall Street.
So what: While Dendreon swung to a fourth-quarter profit of $38.1 million, a big revenue miss -- just $77 million versus the consensus of $121 million -- is forcing analysts to lower their growth expectations yet again. Slow adoption of its prostate cancer drug Provenge continues to weigh on sales, and judging from today's plunge, Wall Street doesn't expect things to turn anytime soon.
Now what: Not surprisingly, management also warned of slowing top-line growth in the current quarter. "Dendreon has embraced the challenge of introducing an entirely new treatment paradigm for an entirely new market and has made important progress towards establishing Provenge as the foundation of care," CEO John Johnson said. With the stock now down a whopping 70% from its April highs, Dendreon seems like decent opportunity for those who like to dig through the trash.
Interested in more info on Dendreon? Add it to your watchlist.